Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Poseida Therapeutics stock

Own Poseida Therapeutics stock in just a few minutes.

Poseida Therapeutics, Inc is a biotechnology business based in the US. Poseida Therapeutics shares (PSTX) are listed on the NASDAQ and all prices are listed in US Dollars. Poseida Therapeutics employs 206 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Poseida Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PSTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Poseida Therapeutics share price

Use our graph to track the performance of PSTX stocks over time.

Poseida Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$7.63 - $17.62
50-day moving average $9.52
200-day moving average $10.08
Wall St. target price$25.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Poseida Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Poseida Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Poseida Therapeutics financials

Gross profit TTM $0
Return on assets TTM -30.51%
Return on equity TTM -77.27%
Profit margin 0%
Book value N/A
Market capitalisation $526.9 million

TTM: trailing 12 months

Shorting Poseida Therapeutics shares

There are currently 3.8 million Poseida Therapeutics shares held short by investors – that's known as Poseida Therapeutics's "short interest". This figure is 16.1% up from 3.2 million last month.

There are a few different ways that this level of interest in shorting Poseida Therapeutics shares can be evaluated.

Poseida Therapeutics's "short interest ratio" (SIR)

Poseida Therapeutics's "short interest ratio" (SIR) is the quantity of Poseida Therapeutics shares currently shorted divided by the average quantity of Poseida Therapeutics shares traded daily (recently around 535808.53485064). Poseida Therapeutics's SIR currently stands at 7.03. In other words for every 100,000 Poseida Therapeutics shares traded daily on the market, roughly 7030 shares are currently held short.

However Poseida Therapeutics's short interest can also be evaluated against the total number of Poseida Therapeutics shares, or, against the total number of tradable Poseida Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Poseida Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Poseida Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1212% of the tradable shares (for every 100,000 tradable Poseida Therapeutics shares, roughly 121 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Poseida Therapeutics.

Find out more about how you can short Poseida Therapeutics stock.

Poseida Therapeutics share dividends

We're not expecting Poseida Therapeutics to pay a dividend over the next 12 months.

Poseida Therapeutics overview

Poseida Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site